Gilead Sciences | GILD - Betriebsergebnis

Aktienkurs
144.01
Täglich Wechseln
-1.13 -0.78%
Monatlich
-5.06%
Jährlich
22.66%
Q1 Prognose
144.39




Betriebsergebnis Veränderung Datum
AbbVie USD 5.81B 1.23B 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Coherus Biosciences USD -45.43M 3.13M 2025-03
Eli Lilly USD 8.99B 599.9M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 3.76B 1.32B 2025-09
Incyte USD 383.88M 47.43M 2025-12
J&J USD 5.59B 1.81B 2025-12
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.5B 363M 2025-09
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.7B 2.17B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12